New COVID-19 vaccine can help develop antibodies in one month, claims Chinese biotech firm

(Karachi) A Chinese biotech company has claimed that its new coronavirus vaccine can help people develop COVID-19 antibodies within one month, media reported.

As per details, Sinovac Biotech Ltd CEO Yin Weidong said the current phase I and II clinical trials of the vaccine have achieved good results, as all of the volunteers who were inoculated the vaccine developed antibodies and none of them are showing adverse reactions.

He added, "More than 1,000 volunteers have had our COVID-19 vaccine, and no more than five percent of them have showed mild fatigue and other uncomfortable symptoms. After vaccination, almost all of them, or statistically about 97 percent to 98 percent of them, have developed antibodies."

The company's CEO maintained, "The volunteers also haven't showed adverse reactions, but all have developed antibodies, and they are comprehensive antibodies. So it should be said that the current phase I and II clinical trails have achieved very good results."

He pointed out, "The current immunization procedure is a 0-14 model, that is, the second injection will be given 14 days after the first injection, or be given 28 days after the first injection. After those two procedures, you will have developed COVID-19 antibodies within one month."

Earlier, China announced to provide coronavirus vaccine to Pakistan to vaccinate the most vulnerable among its population, including the elderly, healthcare workers and people with medical conditions associated with serious cases of Covid-19.

China has reached one of its first agreements to test its coronavirus vaccine in populations beyond its borders.

About one-fifth of the country’s population could be covered by the allocation while Pakistan is also negotiating with another Chinese company to conduct trials of its vaccine in the country.

The state-owned China National Pharmaceutical Group, commonly known as Sinopharm, has teamed up with Karachi University’s International Centre for Chemical and Biological Sciences to hold the trials in Pakistan.